Latest news with #DanGreenhaus
CNBC
03-06-2025
- Business
- CNBC
Cautious on market reaction to upcoming economic data after tariff shock, says Solus' Dan Greenhaus
Dan Greenhaus, Solus Alternative Management, joins 'Closing Bell' to discuss if it'll be a 'summer sizzle' for stocks in the season, Greenhaus' thoughts on bond markets and much more.
Yahoo
21-04-2025
- Business
- Yahoo
Is NexGen Energy Ltd. (NYSE:NXE) the Most Promising Penny Stock According to Analysts?
We recently published a list of the . In this article, we are going to take a look at where NexGen Energy Ltd. (NYSE:NXE) stands against other promising penny stocks. Solus' Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns. The discussion started with Dan Greenhaus expressing his belief that many worst-case scenarios are already priced into the market. He acknowledged that he's cautious but not overly worried. He pointed out recent events, like the exemptions on auto part imports and the 90-day delay on tariff implementation, as evidence that President Trump is listening to advisors and avoiding pushing toward extreme outcomes. Greenhaus attributed these actions to the rebound seen in the stock market. At the same time, he agreed that the administration has been rather inconsistent, in the context of Morgan Stanley's comment that investors should prepare for more inconsistencies. But he argued that many investors are assuming scenarios closer to the worst rather than the best. He emphasized that while frightening predictions about skyrocketing prices are taking over media right now, these scenarios are unlikely to materialize. Brian Levitt built on Greenhaus' optimism while acknowledging the ongoing uncertainty as well. He attributed this uncertainty to the reliance on decisions from the White House rather than traditional policy mechanisms. He compared the current situation to 2018 when markets fell 20% in a quarter before rebounding due to trade pauses and Fed intervention. He cautioned that the current S&P 500 multiples are not at recession levels so there are potential downside risks if uncertainty remains. While Levitt thinks that business investment and consumer confidence metrics show signs of prolonged volatility, Greenhaus further emphasizes that periods of heightened uncertainty often end up presenting long-term investment opportunities. He acknowledged risks such as sudden tariff increases but also encouraged investors to take advantage of these moments when risk premiums rise. We sifted through the Finviz stock screener to compile a list of the top penny stocks that were trading below $5 and had the highest analysts' upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Note: All data was sourced on April 15. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A miner in a hard hat and apron holding a piece of uranium ore in the Athabasca Basin, Saskatchewan. Share Price as of April 15: $4.61 Number of Hedge Fund Holders: 37 Average Upside Potential as of April 15: 90.92% NexGen Energy Ltd. (NYSE:NXE) is an exploration and development stage company. It acquires, explores, evaluates, and develops uranium properties in Canada. It holds a 100% interest in the Rook I project which consists of 32 contiguous mineral claims that total an area of ~35,065 hectares located in the southwestern Athabasca Basin of Saskatchewan. NexGen's flagship Rook I Project is being developed into the largest low-cost producing uranium mine globally. The Rook I Project is built under the most elite environmental and social governance standards. Notably, the company's Arrow Deposit, which is a part of the Rook I project, has seen a 70% jump in pre-production cost, from CAD$1.3 billion to CAD$2.2 billion, causing its IRR to fall from 71.5% to 39.6%. In December 2024, NexGen signed its first agreements with US utility companies to supply 5 million pounds of the nuclear fuel ingredient. NexGen Energy Ltd. (NYSE:NXE) also announced the beginning of a 43,000-meter exploration drill program at Patterson Corridor East, which lies in the world-class Arrow deposit. This program will be one of the largest drill programs in the Athabasca Basin, Saskatchewan in 2025. The company anticipates annual delivery of about 1 million pounds of uranium from 2029 to 2033. L1 Long Short Fund stated the following regarding NexGen Energy Ltd. (NYSE:NXE) in its Q2 2024 investor letter: 'NexGen Energy Ltd. (NYSE:NXE) (Long -10%) weakened as uranium prices fell -7% over the quarter. We continue to see the uranium market as having positive fundamental supply/demand tailwinds over the medium to long term. NexGen is preparing to develop the world's largest undeveloped uranium deposit, Arrow, located in Saskatchewan, Canada. This would be a major, new, strategic Western source to address the anticipated uranium market deficit. We anticipate that NexGen will have completed all regulatory requirements over the course of 2024, providing a clear pathway to full scale construction of the project. Arrow has the potential to generate more than C$2b of cash flow annually, once developed (2028) – a highly attractive proposition given NexGen's current market cap of ~C$5.5b.' Overall, NXE ranks 8th on our list of the most promising penny stocks according to analysts. While we acknowledge the growth potential of NXE, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NXE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
20-04-2025
- Business
- Yahoo
Transocean Ltd. (RIG): Among the Most Promising Penny Stocks According to Analysts
We recently published a list of the . In this article, we are going to take a look at where Transocean Ltd. (NYSE:RIG) stands against other promising penny stocks. Solus' Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns. The discussion started with Dan Greenhaus expressing his belief that many worst-case scenarios are already priced into the market. He acknowledged that he's cautious but not overly worried. He pointed out recent events, like the exemptions on auto part imports and the 90-day delay on tariff implementation, as evidence that President Trump is listening to advisors and avoiding pushing toward extreme outcomes. Greenhaus attributed these actions to the rebound seen in the stock market. At the same time, he agreed that the administration has been rather inconsistent, in the context of Morgan Stanley's comment that investors should prepare for more inconsistencies. But he argued that many investors are assuming scenarios closer to the worst rather than the best. He emphasized that while frightening predictions about skyrocketing prices are taking over media right now, these scenarios are unlikely to materialize. Brian Levitt built on Greenhaus' optimism while acknowledging the ongoing uncertainty as well. He attributed this uncertainty to the reliance on decisions from the White House rather than traditional policy mechanisms. He compared the current situation to 2018 when markets fell 20% in a quarter before rebounding due to trade pauses and Fed intervention. He cautioned that the current S&P 500 multiples are not at recession levels so there are potential downside risks if uncertainty remains. While Levitt thinks that business investment and consumer confidence metrics show signs of prolonged volatility, Greenhaus further emphasizes that periods of heightened uncertainty often end up presenting long-term investment opportunities. He acknowledged risks such as sudden tariff increases but also encouraged investors to take advantage of these moments when risk premiums rise. We sifted through the Finviz stock screener to compile a list of the top penny stocks that were trading below $5 and had the highest analysts' upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Note: All data was sourced on April 15. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). An aerial view of an oil rig with drillers in hard hats working on the platform. Share Price as of April 15: $2.22 Number of Hedge Fund Holders: 38 Average Upside Potential as of April 15: 85.81% Transocean Ltd. (NYSE:RIG) provides offshore contract drilling services for oil and gas wells. It contracts mobile offshore drilling rigs, related equipment, and work crews to drill oil and gas wells. It also operates a fleet of mobile offshore drilling units, which consists of ultra-deepwater floaters and harsh environment floaters. The company heavily relies on its fleet of high-specification drillships, specifically the seventh-generation plus and eighth-generation rigs. In 2024, these advanced assets secured premium contracts. Day rates exceeded $500,000 for the seventh-gen plus rigs and crossed $600,000 for the eighth-generation 20k assets. Transocean's existing fleet is almost fully booked through 2026. The company is now focused on securing new contracts for mid to late 2026 and beyond, targeting these high-specification drillships again. In 2024, Transocean Ltd. (NYSE:RIG) achieved a major industry milestone by installing the first two 20k subsea completions on its eighth-generation drillships. It's also implementing advanced automation systems like IntelliWell, which enable safer and more efficient drilling operations. This includes handling over 1.5 million feet of drill pipe with zero personnel in hazardous zones. Overall, RIG ranks 9th on our list of the most promising penny stocks according to analysts. While we acknowledge the growth potential of RIG, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RIG but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
20-04-2025
- Business
- Yahoo
Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts
We recently published a list of the . In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other promising penny stocks. Solus' Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns. The discussion started with Dan Greenhaus expressing his belief that many worst-case scenarios are already priced into the market. He acknowledged that he's cautious but not overly worried. He pointed out recent events, like the exemptions on auto part imports and the 90-day delay on tariff implementation, as evidence that President Trump is listening to advisors and avoiding pushing toward extreme outcomes. Greenhaus attributed these actions to the rebound seen in the stock market. At the same time, he agreed that the administration has been rather inconsistent, in the context of Morgan Stanley's comment that investors should prepare for more inconsistencies. But he argued that many investors are assuming scenarios closer to the worst rather than the best. He emphasized that while frightening predictions about skyrocketing prices are taking over media right now, these scenarios are unlikely to materialize. Brian Levitt built on Greenhaus' optimism while acknowledging the ongoing uncertainty as well. He attributed this uncertainty to the reliance on decisions from the White House rather than traditional policy mechanisms. He compared the current situation to 2018 when markets fell 20% in a quarter before rebounding due to trade pauses and Fed intervention. He cautioned that the current S&P 500 multiples are not at recession levels so there are potential downside risks if uncertainty remains. While Levitt thinks that business investment and consumer confidence metrics show signs of prolonged volatility, Greenhaus further emphasizes that periods of heightened uncertainty often end up presenting long-term investment opportunities. He acknowledged risks such as sudden tariff increases but also encouraged investors to take advantage of these moments when risk premiums rise. We sifted through the Finviz stock screener to compile a list of the top penny stocks that were trading below $5 and had the highest analysts' upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Note: All data was sourced on April 15. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A chemist arranging containers of compounds, ready for the commercialization process. Share Price as of April 15: $2.57 Number of Hedge Fund Holders: 37 Average Upside Potential as of April 15: 561.48% Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process by enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its lead product candidates include RLY-2608, PI3Ka, and aGal chaperone. RLY-2608 is a candidate for metastatic breast cancer. On March 27, Barclays reiterated its Overweight rating on the stock and maintained a 12-month stock price target of $17 per share. Interim Phase 1b data for RLY-2608 combined with fulvestrant showed an 11.4-month median progression-free survival (PFS) in second-line patients and a 39% confirmed overall response rate (ORR) in patients with measurable disease. Relay plans to initiate the Phase 3 ReDiscover-2 trial in mid-2025. Relay ended Q4 with $781.3 million in cash and investments, which is enough to continue the ongoing clinical trials. The company is prioritizing these funds to support the execution of the ReDiscover-2 Phase 3 trial. In 2024, Relay Therapeutics, Inc. (NASDAQ:RLAY) made $10 million in revenue, which was down from $25.5 million year-over-year. This decline was fueled by milestone payments from the Relay's license agreements. However, the R&D costs were lower than the previous year and reached $319.1 million in 2024. Overall, RLAY ranks 1st on our list of the most promising penny stocks according to analysts. While we acknowledge the growth potential of RLAY, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RLAY but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
20-04-2025
- Business
- Yahoo
Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts
We recently published a list of the . In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against other promising penny stocks. Solus' Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns. The discussion started with Dan Greenhaus expressing his belief that many worst-case scenarios are already priced into the market. He acknowledged that he's cautious but not overly worried. He pointed out recent events, like the exemptions on auto part imports and the 90-day delay on tariff implementation, as evidence that President Trump is listening to advisors and avoiding pushing toward extreme outcomes. Greenhaus attributed these actions to the rebound seen in the stock market. At the same time, he agreed that the administration has been rather inconsistent, in the context of Morgan Stanley's comment that investors should prepare for more inconsistencies. But he argued that many investors are assuming scenarios closer to the worst rather than the best. He emphasized that while frightening predictions about skyrocketing prices are taking over media right now, these scenarios are unlikely to materialize. Brian Levitt built on Greenhaus' optimism while acknowledging the ongoing uncertainty as well. He attributed this uncertainty to the reliance on decisions from the White House rather than traditional policy mechanisms. He compared the current situation to 2018 when markets fell 20% in a quarter before rebounding due to trade pauses and Fed intervention. He cautioned that the current S&P 500 multiples are not at recession levels so there are potential downside risks if uncertainty remains. While Levitt thinks that business investment and consumer confidence metrics show signs of prolonged volatility, Greenhaus further emphasizes that periods of heightened uncertainty often end up presenting long-term investment opportunities. He acknowledged risks such as sudden tariff increases but also encouraged investors to take advantage of these moments when risk premiums rise. We sifted through the Finviz stock screener to compile a list of the top penny stocks that were trading below $5 and had the highest analysts' upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Note: All data was sourced on April 15. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A group of scientists in a laboratory researching a sophisticated biotechnology drug. Share Price as of April 15: $4.58 Number of Hedge Fund Holders: 38 Average Upside Potential as of April 15: 249.34% Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotech company that develops precision therapies for genetically defined diseases. Its lead product candidate is bezuclastinib (CGT9486), which is a selective tyrosine kinase inhibitor in a Phase 3 trial. It is designed to target mutations within the KIT receptor tyrosine kinase, which includes the KIT D816V mutation that drives systemic mastocytosis (SM), as well as other mutations found in patients with advanced gastrointestinal stromal tumors. Cogent has a cash position worth $312 million, which will sustain its operations into late 2026. Its R&D expenses rose to $62 million in Q4 2024 and $232.7 million for the full year due to the accelerated development of Bezuclastinib and other research programs. In February, Cogent presented promising updates from the SUMMIT and APEX trials at the American Society of Hematology (ASH) meeting. It showed improvements in non-advanced SM and encouraging results in advanced SM patients. In the SUMMIT, patients on 100 mg of bezuclastinib showed a 56% average improvement in symptoms after 24 weeks. In the APEX trial, bezuclastinib achieved a 52% overall response rate (ORR) per mIWG criteria. Cogent Biosciences, Inc. (NASDAQ:COGT) expects top-line results from the SUMMIT trial in July 2025 and the APEX trial in H2 2025. It plans to submit the first NDA for bezuclastinib by the end of 2025. Overall, COGT ranks 4th on our list of the most promising penny stocks according to analysts. While we acknowledge the growth potential of COGT, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than COGT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
